ATE491043T1 - Diagnosegerät zur diagnose gutartiger gegenüber bösartigen schilddrüsenläsionen - Google Patents

Diagnosegerät zur diagnose gutartiger gegenüber bösartigen schilddrüsenläsionen

Info

Publication number
ATE491043T1
ATE491043T1 AT05735973T AT05735973T ATE491043T1 AT E491043 T1 ATE491043 T1 AT E491043T1 AT 05735973 T AT05735973 T AT 05735973T AT 05735973 T AT05735973 T AT 05735973T AT E491043 T1 ATE491043 T1 AT E491043T1
Authority
AT
Austria
Prior art keywords
diagnosis
diagnostic device
malignant thyroid
thyroid lesions
versus malignant
Prior art date
Application number
AT05735973T
Other languages
English (en)
Inventor
Steven Libutti
Chiara Mazzanti
Martha A Zeiger
Christopher B Umbricht
Original Assignee
Us Gov Health & Human Serv
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Univ Johns Hopkins filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE491043T1 publication Critical patent/ATE491043T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Test And Diagnosis Of Digital Computers (AREA)
  • Monitoring And Testing Of Transmission In General (AREA)
  • Stereo-Broadcasting Methods (AREA)
AT05735973T 2004-04-09 2005-04-11 Diagnosegerät zur diagnose gutartiger gegenüber bösartigen schilddrüsenläsionen ATE491043T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56090004P 2004-04-09 2004-04-09
US62264304P 2004-10-26 2004-10-26
PCT/US2005/012289 WO2005100608A2 (en) 2004-04-09 2005-04-11 Diagnostic tool for diagnosing benign versus malignant thyroid lesions

Publications (1)

Publication Number Publication Date
ATE491043T1 true ATE491043T1 (de) 2010-12-15

Family

ID=35150567

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05735973T ATE491043T1 (de) 2004-04-09 2005-04-11 Diagnosegerät zur diagnose gutartiger gegenüber bösartigen schilddrüsenläsionen

Country Status (5)

Country Link
US (2) US7901881B2 (de)
EP (1) EP1756303B1 (de)
AT (1) ATE491043T1 (de)
DE (1) DE602005025211D1 (de)
WO (1) WO2005100608A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005100608A2 (en) * 2004-04-09 2005-10-27 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Diagnostic tool for diagnosing benign versus malignant thyroid lesions
JP2007199948A (ja) * 2006-01-25 2007-08-09 Dainakomu:Kk 疾患リスク情報表示装置およびプログラム
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
EP1975252A1 (de) * 2007-03-29 2008-10-01 INSERM (Institut National de la Santé et de la Recherche Medicale) Verfahren zur Vorhersage oder Diagnose einer Schilddrüsenkrankheit
US9234244B2 (en) * 2007-08-27 2016-01-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diagnostic tool for diagnosing benign versus malignant thyroid lesions
AU2009253675A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
WO2010030365A2 (en) 2008-09-12 2010-03-18 Cornell Research Foundation, Inc. Wmc Thyroid tumors identified
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
CA3153682A1 (en) * 2008-11-17 2010-05-20 Veracyte, Inc. Methods and compositions of molecular profiling for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
US9206482B2 (en) 2009-04-29 2015-12-08 Genomedx Biosciences Inc. Systems and methods for expression-based classification of thyroid tissue
JP6078339B2 (ja) 2009-05-07 2017-02-08 ベラサイト インコーポレイテッド 甲状腺状態の診断のための方法および組成物
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
WO2011079846A2 (en) 2009-12-30 2011-07-07 Rigshospitalet Mrna classification of thyroid follicular neoplasia
US8708914B2 (en) 2010-06-07 2014-04-29 Atheropoint, LLC Validation embedded segmentation method for vascular ultrasound images
US8639008B2 (en) * 2010-04-20 2014-01-28 Athero Point, LLC Mobile architecture using cloud for data mining application
US8485975B2 (en) 2010-06-07 2013-07-16 Atheropoint Llc Multi-resolution edge flow approach to vascular ultrasound for intima-media thickness (IMT) measurement
US8532360B2 (en) 2010-04-20 2013-09-10 Atheropoint Llc Imaging based symptomatic classification using a combination of trace transform, fuzzy technique and multitude of features
US8313437B1 (en) 2010-06-07 2012-11-20 Suri Jasjit S Vascular ultrasound intima-media thickness (IMT) measurement system
US20190100809A1 (en) * 2010-05-11 2019-04-04 Veracyte, Inc. Algorithms for disease diagnostics
CN106498076A (zh) * 2010-05-11 2017-03-15 威拉赛特公司 用于诊断病状的方法和组合物
AU2012352153B2 (en) 2011-12-13 2018-07-26 Veracyte, Inc. Cancer diagnostics using non-coding transcripts
EP4219765A3 (de) 2012-08-16 2023-09-20 Decipher Biosciences, Inc. Prostatakrebsprognose unter verwendung von biomarkern
KR101993716B1 (ko) * 2012-09-28 2019-06-27 삼성전자주식회사 카테고리별 진단 모델을 이용한 병변 진단 장치 및 방법
US10526655B2 (en) 2013-03-14 2020-01-07 Veracyte, Inc. Methods for evaluating COPD status
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
EP3215170A4 (de) 2014-11-05 2018-04-25 Veracyte, Inc. Systeme und verfahren zur diagnose von idiopathischer pulmonaler fibrose auf transbronchialen biopsien mit maschinellem lernen und hochdimensionalen transkriptionsdaten
WO2018039490A1 (en) 2016-08-24 2018-03-01 Genomedx Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
US11208697B2 (en) 2017-01-20 2021-12-28 Decipher Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
EP3593140A4 (de) 2017-03-09 2021-01-06 Decipher Biosciences, Inc. Subtypisierung von prostatakrebs zur vorhersage der reaktion auf eine hormontherapie
CA3062716A1 (en) 2017-05-12 2018-11-15 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
EP4023770A1 (de) 2021-01-05 2022-07-06 Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Oddzial w Gliwicach Verfahren zur untersuchung von genen zur diagnose von schilddrüsentumoren, set zur diagnose von schilddrüsentumoren und anwendung

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5578832A (en) * 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5631734A (en) * 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US5571639A (en) * 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5556752A (en) * 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US6974666B1 (en) 1994-10-21 2005-12-13 Appymetric, Inc. Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA
US5599695A (en) * 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
JP2002515738A (ja) 1996-01-23 2002-05-28 アフィメトリックス，インコーポレイティド 核酸分析法
EP0937159A4 (de) 1996-02-08 2004-10-20 Affymetrix Inc Speziesbestimmung und phenotypische charakterisierung von mikroorganismen auf der basis eines chips
US6458530B1 (en) 1996-04-04 2002-10-01 Affymetrix Inc. Selecting tag nucleic acids
US6436642B1 (en) * 1999-04-20 2002-08-20 Curagen Corporation Method of classifying a thyroid carcinoma using differential gene expression
US20040219521A1 (en) * 2000-01-21 2004-11-04 Tang Y. Tom Novel nucleic acids and polypeptides
WO2003025135A2 (en) 2001-09-14 2003-03-27 Gene Logic, Inc. Genes associated with malignant neoplasms
EP1504099A4 (de) * 2001-12-10 2006-05-10 Nuvelo Inc Neue nukleinsäuren und polypeptide
WO2003065873A2 (en) 2002-02-01 2003-08-14 Seattle Genetics, Inc. Sga-1m, a cancer associated antigen, and uses thereof
CA2488382A1 (en) 2002-06-05 2003-12-18 Case Western Reserve University Methods and compositions for detecting cancers
WO2005100608A2 (en) 2004-04-09 2005-10-27 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Diagnostic tool for diagnosing benign versus malignant thyroid lesions

Also Published As

Publication number Publication date
EP1756303A2 (de) 2007-02-28
US20080145841A1 (en) 2008-06-19
US7901881B2 (en) 2011-03-08
US20110177971A1 (en) 2011-07-21
EP1756303B1 (de) 2010-12-08
WO2005100608A3 (en) 2006-06-15
DE602005025211D1 (de) 2011-01-20
WO2005100608A2 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
ATE491043T1 (de) Diagnosegerät zur diagnose gutartiger gegenüber bösartigen schilddrüsenläsionen
WO2009029266A3 (en) Diagnostic tool for diagnosing benign versus malignant thyroid lesions
WO2008050255A3 (en) Contrast agents for detecting prostate cancer
MX2010000405A (es) Seleccion de farmacos para terapia de cancer de pulmon usando arreglos a base de anticuerpos.
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
WO2008008786A3 (en) Pre- and intra- operative imaging of bladder cancer
WO2008060363A3 (en) Tumor associated markers in the diagnosis of prostate cancer
IL207637A (en) Choosing a Breast Cancer Remedy Using Antibody-Based Arrays
WO2005111211A3 (en) Micronas and uses thereof
WO2005044990A3 (en) Use of differentially expressed nucleic acid sequences as biomarkers for cancer
WO2005123993A3 (en) Phage microarray profiling of the humoral response to disease
MX2007016322A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
WO2009009223A8 (en) Co-registration for dual pet-transrectal ultrasound (pet-trus) prostate imaging
WO2004070062A3 (en) Compositions and methods for diagnosing and treating cancers
EP1937845A4 (de) Verfahren und zusammensetzungen auf mikro-rna-basis zur diagnose, prognose und behandlung von brustkrebs
NO20071791L (no) Preparater og fremgangsmater for diagnostiseringen og behandlingen av tumor
FR2883562B1 (fr) Chelates lipophiles et leur utilisation en imagerie
WO2004065583A3 (en) Gene expression markers for breast cancer prognosis
WO2007143037A3 (en) Gene methylation in cancer diagnosis
EP1848466A4 (de) Mri-kontrastmittel zur diagnose und prognose von tumoren
WO2006015079A3 (en) Erm family binding agents and their use in diagnosis and treatment of proliferative conditions
WO2013096845A3 (en) Methods for diagnosis of lung cancer
IL201778A0 (en) Peptide imaging agents
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2007033167A3 (en) Compositions and methods for detecting and treating cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties